Dr. Sei-Gyung K. Sze
Claim this profileMaine Children's Cancer Program
Area of expertise
Neuroblastoma
Sei-Gyung K. Sze has run 2 trials for Neuroblastoma. Some of their research focus areas include:
Acute Lymphoblastic Leukemia
Sei-Gyung K. Sze has run 2 trials for Acute Lymphoblastic Leukemia. Some of their research focus areas include:
Affiliated Hospitals
Maine Children's Cancer Program
Clinical Trials Sei-Gyung K. Sze is currently running
Levocarnitine
for Chemotherapy-Related Liver Protection in Leukemia and Lymphoma
This phase III trial compares the effect of adding levocarnitine to standard chemotherapy versus (vs.) standard chemotherapy alone in protecting the liver in patients with leukemia or lymphoma. Asparaginase is part of the standard of care chemotherapy for the treatment of acute lymphoblastic leukemia (ALL), lymphoblastic lymphoma (LL), and mixed phenotype acute leukemia (MPAL). However, in adolescent and young adults (AYA) ages 15-39 years, liver toxicity from asparaginase is common and often prevents delivery of planned chemotherapy, thereby potentially compromising outcomes. Some groups of people may also be at higher risk for liver damage due to the presence of fat in the liver even before starting chemotherapy. Patients who are of Japanese descent, Native Hawaiian, Hispanic or Latinx may be at greater risk for liver damage from chemotherapy for this reason. Carnitine is a naturally occurring nutrient that is part of a typical diet and is also made by the body. Carnitine is necessary for metabolism and its deficiency or absence is associated with liver and other organ damage. Levocarnitine is a drug used to provide extra carnitine. Laboratory and real-world usage of the dietary supplement levocarnitine suggests its potential to prevent or reduce liver toxicity from asparaginase. The overall goal of this study is to determine whether adding levocarnitine to standard of care chemotherapy will reduce the chance of developing severe liver damage from asparaginase chemotherapy in ALL, LL and/or MPAL patients.
Recruiting
2 awards
Phase 3
Dinutuximab + Chemotherapy
for High-Risk Neuroblastoma
This phase III trial tests how well the addition of dinutuximab to Induction chemotherapy along with standard of care surgical resection of the primary tumor, radiation, stem cell transplantation, and immunotherapy works for treating children with newly diagnosed high-risk neuroblastoma. Dinutuximab is a monoclonal antibody that binds to a molecule called GD2, which is found on the surface of neuroblastoma cells, but is not present on many healthy or normal cells in the body. When dinutuximab binds to the neuroblastoma cells, it helps signal the immune system to kill the tumor cells. This helps the cells of the immune system kill the cancer cells, this is a type of immunotherapy. When chemotherapy and immunotherapy are given together, during the same treatment cycle, it is called chemoimmunotherapy. This clinical trial randomly assigns patients to receive either standard chemotherapy and surgery or chemoimmunotherapy (chemotherapy plus dinutuximab) and surgery during Induction therapy. Chemotherapy drugs administered during Induction include, cyclophosphamide, topotecan, cisplatin, etoposide, vincristine, and doxorubicin. These drugs work in different ways to stop the growth of cancer cells, either by killing the cells, by stopping them from dividing or by stopping them from spreading. Upon completion of 5 cycles of Induction therapy, a disease evaluation is completed to determine how well the treatment worked. If the tumor responds to therapy, patients receive a tandem transplantation with stem cell rescue. If the tumor has little improvement or worsens, patients receive chemoimmunotherapy on Extended Induction. During Extended Induction, dinutuximab is given with irinotecan, temozolomide. Patients with a good response to therapy move on to Consolidation therapy, when very high doses of chemotherapy are given at two separate points to kill any remaining cancer cells. Following, transplant, radiation therapy is given to the site where the cancer originated (primary site) and to any other areas that are still active at the end of Induction. The final stage of therapy is Post-Consolidation. During Post-Consolidation, dinutuximab is given with isotretinoin, with the goal of maintaining the response achieved with the previous therapy. Adding dinutuximab to Induction chemotherapy along with standard of care surgical resection of the primary tumor, radiation, stem cell transplantation, and immunotherapy may be better at treating children with newly diagnosed high-risk neuroblastoma.
Recruiting
2 awards
Phase 3
7 criteria
More about Sei-Gyung K. Sze
Clinical Trial Related
2 years of experience running clinical trials · Led 4 trials as a Principal Investigator · 3 Active Clinical Trials
Treatments Sei-Gyung K. Sze has experience with
- Dinutuximab
- Eflornithine Hydrochloride
- Irinotecan Hydrochloride
- Temozolomide
- Biospecimen Collection
- Levocarnitine
Breakdown of trials Sei-Gyung K. Sze has run
Neuroblastoma
Acute Lymphoblastic Leukemia
Acute Leukemia
Biphenotypic Leukemia
Other Doctors you might be interested in
Frequently asked questions
Do I need insurance to participate in a trial?
Almost all clinical trials will cover the cost of the ‘trial drug’ — so no insurance is required for this. For trials where this trial drug is given alongside an already-approved medication, there may be a cost (which your insurance would normally cover).
What does Sei-Gyung K. Sze specialize in?
Sei-Gyung K. Sze focuses on Neuroblastoma and Acute Lymphoblastic Leukemia. In particular, much of their work with Neuroblastoma has involved Stage IV patients, or patients who are MYC positive.
Is Sei-Gyung K. Sze currently recruiting for clinical trials?
Yes, Sei-Gyung K. Sze is currently recruiting for 3 clinical trials in Scarborough Maine. If you're interested in participating, you should apply.
Are there any treatments that Sei-Gyung K. Sze has studied deeply?
Yes, Sei-Gyung K. Sze has studied treatments such as Dinutuximab, Eflornithine Hydrochloride, Irinotecan Hydrochloride.
What is the best way to schedule an appointment with Sei-Gyung K. Sze?
Apply for one of the trials that Sei-Gyung K. Sze is conducting.
What is the office address of Sei-Gyung K. Sze?
The office of Sei-Gyung K. Sze is located at: Maine Children's Cancer Program, Scarborough, Maine 04074 United States. This is the address for their practice at the Maine Children's Cancer Program.
Is there any support for travel costs?
The coverage of travel expenses can vary greatly between different clinical trials. Please see more financial detail in the trials you’re interested to apply.
Unbiased Results
We believe in providing patients with all the options.
Your Data Stays Your Data
We only share your information with the clinical trials you're trying to access.
Verified Trials Only
All of our trials are run by licensed doctors, researchers, and healthcare companies.